Gene Signature In Breast Cancer Research Articles

Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer

BackgroundPublished prognostic gene signatures in breast cancer have few genes in common. Here we provide a rationale for this observation by studying the prognostic power and the underlying biological pathways of different gene signatures.MethodsGene signatures to predict the development of metastases in estrogen receptor-positive and estrogen receptor-negative tumors were identified using 500 re-sampled training sets and mapping to Gene Ontology Biological Process to identify over-represented pathways. The Global Test program confirmed that gene expression profilings in the common pathways were associated with the metastasis of the patients.ResultsThe apoptotic pathway and cell division, or cell growth regulation and G-protein coupled receptor signal transduction, were most significantly associated with the metastatic capability of estrogen receptor-positive or estrogen-negative tumors, respectively. A gene signature derived of the common pathways predicted metastasis in an independent cohort. Mapping of the pathways represented by different published prognostic signatures showed that they share 53% of the identified pathways.ConclusionWe show that divergent gene sets classifying patients for the same clinical endpoint represent similar biological processes and that pathway-derived signatures can be used to predict prognosis. Furthermore, our study reveals that the underlying biology related to aggressiveness of estrogen receptor subgroups of breast cancer is quite different.

2056 POSTER A cross-study verification of breast cancer gene signature in peripheral blood

The Okwa Basement Complex crops out at the northwestern edge of the Kaapvaal craton within the Okwa Inlier, an isolated exposure of Precambrian basement in the Kalahari Desert. New U–Pb zircon dating was performed on all the major Palaeoproterozoic lithologies of the complex. Results are 2055.3 ± 1.3 Ma for augen gneiss, 2056.3 ± 1.3 Ma for foliated monzogranite and 2057 ± 2 Ma for microgranite. A meta-rhyolite gives an age of 2055 ± 4 Ma, based on one concordant zircon, and contains an inherited zircon with an age of 2101 ± 4 Ma. All precisely dated rocks are indistinguishable in age at 2056 ± 2 Ma. This age can be broadly correlated with Palaeoproterozoic geologic events in the Magondi belt at the northwest margin of the Zimbabwe craton and the Triangle Shear Zone in the Limpopo belt. However, the most precise correlation is with the Bushveld Complex, whose age is indistinguishable from that of the Okwa Basement Complex. This suggests a link between marginal and intra-cratonic Bushveld-age magmatism on the Kaapvaal craton.

A Gene Signature in Breast Cancer

Sunnybrook Health Sciences Centre Toronto, ON M4N 3M5, Canada Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808. [Erratum, Lancet Oncol 2005;6:826.] Kerlikowske K. The mammogram that cried Wolfe. N Engl J Med 2007;356:297-300. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69. Pawluczyk O, Augustine BJ, Yaffe MJ, et al. A volumetric method for estimation of breast density on digitized screen-film mammograms. Med Phys 2003;30:352-64. 1.

Prognostic Role of a Gene Signature in Breast Cancer

Just a few years ago, the idea of gene profiling of tumors was viewed as a futuristic concept that would change our approach to patient prognosis and

Robust identification of novel prognostic gene-signatures in breast cancer

Robust identification of novel prognostic gene-signatures in breast cancer

Immortalization-associated gene signature in breast cancer

Immortalization-associated gene signature in breast cancer